What is ZVRA's P/E ratio?

Zevra Therapeutics Inc. (ZVRA) currently trades at a P/E ratio of 10.59.

Zevra Therapeutics Inc. reports a Return on Equity (ROE) of 26.77%.

What is ZVRA's dividend yield?

Zevra Therapeutics Inc. offers a dividend yield of 0.00%.

What is ZVRA's Quality Score?

Our AI rates ZVRA's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ZVRA?

Our AI Timing Score for ZVRA is 30 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ZVRA belong to?

Zevra Therapeutics Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Zevra Therapeutics Inc. (ZVRA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-06 | FS: 2026-06-30)

ZVRA AI Analysis Summary

Our AI summary for ZVRA: Zevra Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 10.59, ROE of 26.77%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 30/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ZVRA

Zevra Therapeutics Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 97

USD 11.88

1.35 (12.82%) Day Change

Watchlist Portfolio Compare Chart

10.59

P/E

0.00

D/E

26.8%

ROE

19.3%

ROA

0.00%

Div Yield

-1.53

PEG

ZEVRA THERAPEUTICS INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 11.88 Price 1.35 (12.82%) Day Change	NEWS SCORE: 97

ZVRA, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

54%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	97
Magic Formula Rank by ROA	165
Magic Formula Rank by ROE	165
Magic Formula Rank by ROIC	175
Price	11.88
PBV / Sector	2.86 / 5.21
Earning Per Share	1.11

PE / Sector	10.59 / 21.00 GOOD
PEG or PE/Growth / Sector	-1.53 / 1.11
Average 1M Daily Value	16.56 M GREAT
Average 1W Daily Value	15.46 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

62%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	42.82 / 95.56 GREAT
NPM Average (%) / Sector	-151.41 / -1,676.77
NPM Change Average (%) / Sector	-8.15 / 4,917.73
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	19.25 / 25.44 GOOD
ROA Average (%) / Sector	-12.14 / -350.66
ROA Change Average (%) / Sector	-11.68 / 5,110.09
ROE (%) / Sector	26.77 / 3.07 GOOD
ROE Average (%) / Sector	-59.10 / 4.81
ROE Change Average (%) / Sector	48.93 / 2,068.02 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.02
Dividend Average (%) / Sector	N/A / 17.10
Dividend Change Average (%) / Sector	N/A / 0.98

Registration Details

Analyze Date	2026-08-07 08:12:36
Symbol	ZVRA
Name	ZEVRA THERAPEUTICS INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	59.12 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	622.48 / 9,672.56

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 101 Federal Street, Boston, MA, United States, 02110

Phone: 888 958 1253

Website: https://www.zevra.com

Employees: 61

Sector: Healthcare >> Biotechnology

Description: Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.